Advertisement
Novara — A Smarter Way to Access Global Markets
Markets desk·updated through the day

Markets

Finland’s OMX Helsinki 25 falls 1.61% as Nokia, Metso weigh on market
EquitiesArticle

Finland’s OMX Helsinki 25 falls 1.61% as Nokia, Metso weigh on market

Telecoms, industrials and technology led declines on the Helsinki exchange. Nokia dropped 7.29% while Metso fell 4.71% as broader benchmark slid.

19 Aug 2026
US stocks mixed pre-market; Moderna surges 72% on Merck trial data
EquitiesArticle

US stocks mixed pre-market; Moderna surges 72% on Merck trial data

SMI edges higher as Moderna jumps on positive melanoma trial results with Merck’s Keytruda. Geberit, Implenia lead Swiss gains; DocMorris, Straumann lag. Brent crude hits $92 amid Iran conflict.

UGI shares surge 14% on KKR takeover report
EquitiesArticle

UGI shares surge 14% on KKR takeover report

Private equity giant KKR reportedly offers $9 billion for UGI Corporation at $42.50 per share, lifting the utility distributor's stock nearly 20% above its pre-announcement level.

US stocks rise as Moderna surges 150% on cancer vaccine data
EquitiesArticle

US stocks rise as Moderna surges 150% on cancer vaccine data

Moderna’s mRNA cancer vaccine trial results drive a 150% jump in its shares, lifting the S&P 500 and Swiss pharma stocks. US net interest payments hit a record 3.3% of GDP.

Nasdaq slips as Moderna surges; US net interest payments hit record high
EquitiesArticle

Nasdaq slips as Moderna surges; US net interest payments hit record high

Moderna’s 72% rally fuels gains in biotech and Swiss pharma shares, while U.S. net interest costs rise to 3.3% of GDP—the highest on record. SMI edges higher as defensive stocks offset semiconductor weakness.

Basilea Pharmaceutica posts 32% profit surge in H1 2026, raises guidance
EquitiesArticle

Basilea Pharmaceutica posts 32% profit surge in H1 2026, raises guidance

Swiss drugmaker reports CHF 27.9 million net profit for the first half, driven by strong Cresemba sales and non-dilutive funding. Full-year outlook upgraded on revenue and profit growth.

US stocks rise as Moderna surges; US net interest costs hit record high
EquitiesArticle

US stocks rise as Moderna surges; US net interest costs hit record high

Moderna’s 118% rally lifts biotech and Swiss pharma; Dow, S&P 500 and Nasdaq 100 advance. US net interest payments climb to 3.3% of GDP, highest on record.

Basilea raises 2026 revenue, profit forecasts after strong H1 results
EquitiesArticle

Basilea raises 2026 revenue, profit forecasts after strong H1 results

Swiss drugmaker posts CHF 119 million in H1 revenue, a 14% rise, and doubles full-year profit guidance as Cresemba and Zevtera sales accelerate.

Wagyu.xyz crosses $700M in volume, opens public API for developers
CryptoArticle

Wagyu.xyz crosses $700M in volume, opens public API for developers

Cross-chain swap platform Wagyu.xyz reaches $700M in cumulative trading volume seven months after launch and introduces a public API for third-party integrations. Median settlement time for Monero swaps stands at 5.5 minutes.

JDC posts record H1 2026 profit, eyes AVD launch in 2027
EquitiesArticle

JDC posts record H1 2026 profit, eyes AVD launch in 2027

First-half revenue rose 18.7% to €143.5 million as AI-driven efficiency gains offset weak contract transfers. Altersvorsorgedepot platform to target 50 million eligible Germans from January.

Conduit Holdings names Mark Pickering as new CFO, effective Nov 2026
EquitiesArticle

Conduit Holdings names Mark Pickering as new CFO, effective Nov 2026

Pickering, former Aspen Insurance CFO, will replace Elaine Whelan and join the board. His appointment follows Aspen’s IPO and acquisition by Sompo earlier this year.

Klarna shares plunge 22% after profit warning, forecast cut
EquitiesArticle

Klarna shares plunge 22% after profit warning, forecast cut

Swedish fintech’s U.S.-listed stock fell sharply after it lowered annual revenue guidance and cited weak performance in its largest market, Germany. CFO and CMO roles to be refilled in 2027.

Shaires Holdings delays retail share offer deadline to Aug 24
EquitiesArticle

Shaires Holdings delays retail share offer deadline to Aug 24

London-based investment firm extends closing date for $20 share offer to Aug 24, 2026, at 4:30 pm, maintaining trading pause until further notice.

TCOMAS to unveil gold limited-edition AIO cooler at Gamescom 2026
CommoditiesArticle

TCOMAS to unveil gold limited-edition AIO cooler at Gamescom 2026

PC hardware brand TCOMAS will debut a gold-themed liquid cooler at Gamescom 2026, alongside a new AI PC configurator and a custom build by MudzieModz. The event runs Aug. 26–30 in Cologne.

TD Cowen flags unresolved questions ahead of Nvidia, Broadcom earnings
EquitiesArticle

TD Cowen flags unresolved questions ahead of Nvidia, Broadcom earnings

Analysts remain neutral on Nvidia and Broadcom despite raised long-term datacenter market estimates, citing unresolved debates over roadmaps and margins.

AUD/JPY outshines peers as carry trade demand rises amid USD softening
ForexArticle

AUD/JPY outshines peers as carry trade demand rises amid USD softening

Australian dollar-yen pair leads currency carry trade alternatives with an 18% annual gain, while Mexican peso and Turkish lira flash caution signals despite some technical buy signals.

Six small-cap energy stocks trading below 7x P/E with 29% average upside
EquitiesArticle

Six small-cap energy stocks trading below 7x P/E with 29% average upside

StealthGas, SandRidge Energy and four others show strong free cash flow yields and minimal leverage amid elevated energy prices. Analyst coverage remains sparse for most names.

S&P affirms Nvidia's AA rating, cites Ohio AI campus guarantee
EquitiesArticle

S&P affirms Nvidia's AA rating, cites Ohio AI campus guarantee

Credit agency S&P Global Ratings maintains Nvidia's AA issuer credit rating with a stable outlook, citing a $105 billion guarantee tied to an Ohio AI data center campus. The rating agency also adjusted future debt projections based on the facility's development schedule.

Basilea Pharmaceutica lifts H1 2026 outlook as stock surges 8.7%
EquitiesArticle

Basilea Pharmaceutica lifts H1 2026 outlook as stock surges 8.7%

Swiss biotech raised its full-year revenue and profit guidance after reporting a 14% revenue jump in H1 2026. Shares rose 8.7% in pre-market trading.